Keywords: celltech, merck, co, extend, pde4, collaboration, drug
Celltech and Merck & Co extend PDE4 collaboration
Article | 29 September 2003
US drug major Merck & Co has exercised its option to extend the development period regarding its phosphodiesterase-4 (PDE4) inhibitors collaboration ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
